What is a stock summary page? Click here for an overview.
Business Description
Exact Sciences Corp
NAICS : 621511
SIC : 8731
ISIN : US30063P1057
Share Class Description:
EXAS: Ordinary SharesDescription
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 1.15 | |||||
| Debt-to-EBITDA | -3.44 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.41 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.2 | |||||
| 3-Year EBITDA Growth Rate | -4.2 | |||||
| 3-Year EPS without NRI Growth Rate | 59.8 | |||||
| 3-Year Book Growth Rate | -12.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.87 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.32 | |||||
| 9-Day RSI | 45.95 | |||||
| 14-Day RSI | 42.81 | |||||
| 3-1 Month Momentum % | -17.07 | |||||
| 6-1 Month Momentum % | -29.72 | |||||
| 12-1 Month Momentum % | -20.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.15 | |||||
| Quick Ratio | 1.92 | |||||
| Cash Ratio | 1.42 | |||||
| Days Inventory | 59.32 | |||||
| Days Sales Outstanding | 32.33 | |||||
| Days Payable | 32.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -1.79 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.55 | |||||
| Operating Margin % | -6.5 | |||||
| Net Margin % | -37.29 | |||||
| FCF Margin % | 2.7 | |||||
| ROE % | -34.11 | |||||
| ROA % | -15.98 | |||||
| ROIC % | -3.28 | |||||
| 3-Year ROIIC % | -64.92 | |||||
| ROC (Joel Greenblatt) % | -112.41 | |||||
| ROCE % | -17.59 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.16 | |||||
| PB Ratio | 3.64 | |||||
| Price-to-Free-Cash-Flow | 119.29 | |||||
| Price-to-Operating-Cash-Flow | 41.46 | |||||
| EV-to-EBIT | -10.06 | |||||
| EV-to-Forward-EBIT | 237 | |||||
| EV-to-EBITDA | -12.76 | |||||
| EV-to-Forward-EBITDA | 60.96 | |||||
| EV-to-Revenue | 3.7 | |||||
| EV-to-Forward-Revenue | 3.33 | |||||
| EV-to-FCF | 133.37 | |||||
| Price-to-GF-Value | 0.66 | |||||
| Price-to-Median-PS-Value | 0.21 | |||||
| Earnings Yield (Greenblatt) % | -9.94 | |||||
| FCF Yield % | 0.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EXAS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exact Sciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,758.867 | ||
| EPS (TTM) ($) | -5.57 | ||
| Beta | 1.7 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 57.46 | ||
| 14-Day RSI | 42.81 | ||
| 14-Day ATR ($) | 2.14962 | ||
| 20-Day SMA ($) | 46.69 | ||
| 12-1 Month Momentum % | -20.55 | ||
| 52-Week Range ($) | 40.624 - 79.62 | ||
| Shares Outstanding (Mil) | 185.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exact Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exact Sciences Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Exact Sciences Corp Frequently Asked Questions
What is Exact Sciences Corp(EXAS)'s stock price today?
The current price of EXAS is $47.11. The 52 week high of EXAS is $79.62 and 52 week low is $40.62.
When is next earnings date of Exact Sciences Corp(EXAS)?
The next earnings date of Exact Sciences Corp(EXAS) is 2025-05-08 Est..
Does Exact Sciences Corp(EXAS) pay dividends? If so, how much?
Exact Sciences Corp(EXAS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers